No Data
No Data
10-Q: Quarterly report
OmniAb Announces Completion of Spin-Off and Business Combination
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
Janssen Biotech Inc, a Johnson & Johnson (NYSE:JNJ) unit, received European conditional approval for Tecvayli (teclistamab) as monotherapy for relapsed or refractory multiple myeloma. Teclistamab
Press Release: Ligand Announces That Janssen Has Received Approval From European Commission for TECVAYLI(R) (Teclistamab) for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI(R) (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma First European Co
Press Release: Ligand Announces That Janssen Has -2-
This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. Words such as "plans," "believes," "e
Ligand Pharmaceuticals Sees FY22 Rev $169M-$188M >LGND
Ligand Pharmaceuticals Sees FY22 Rev $169M-$188M >LGND
No Data